SRIRAM NAGBHUSHAN SHINGNAPURE, LANYA M. AND RADHIKA PILLI
Abstract
Proteases (Fibrinolytic) enzymes have implicit function in cascade system, accelerating the switch of prothrombin to thrombin following degradation of fibrin or blood clots, unfolding the issues of thrombotic disorders related to cardiovascular diseases. Common blood flow obstructions due to embolism and thrombosis leads to cardiovascular diseases (CVDs) such as pulmonary embolism, transient ischemic attack in the brain or neck, heart attack and deep venous thrombosis, resulting in a substantial global health challenge. Current treatments like anti-platelet drugs, anticoagulants, and fibrinolytic protease activators, often available not only in high costs but also cause substantial side effects. As a research investigation, fibrinolytic enzymes from bacteria were isolated from diverse sources, with an ideal goal on their implicit therapy. There were thirty bacterial isolates (SR1 to SR30) procured from homemade fermented and commercial foods and rhizosphere soil in Bangalore East, South India. The screening of enzyme efficiency was accomplished through plate assay and capillary clot digestion. Out of those, eleven strains (SR1 to SR11) showed the evidence of protease activity. These bacterial isolates consummated characterization through Identax identifier software by macroscopic, microscopic, and biochemical tests. Among the eleven, SR11 isolate which was identified as Virgibacillus pantothenticus representing significant fibrinolytic potential by digesting the capillary blood clot in a short period of 5 min. This analysis emphasizes the assurance of bacterial fibrinolytic enzymes, particularly SR11 isolate, as remarkable alternative for treating cardiovascular disorders, entailing advance research to optimize their therapeutic applications.